Published in Cancer Cell on March 14, 2016
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med (2017) 0.98
Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. PLoS One (2016) 0.95
Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget (2016) 0.89
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget (2016) 0.85
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front Oncol (2016) 0.80
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun Signal (2017) 0.78
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
Salmonella typhimurium A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib-temozlomide. Cell Cycle (2017) 0.76
The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol (2016) 0.75
The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Front Immunol (2016) 0.75
Gel-Trapped Lymphorganogenic Chemokines Trigger Artificial Tertiary Lymphoid Organs and Mount Adaptive Immune Responses In Vivo. Front Immunol (2016) 0.75
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology (2017) 0.75
Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy? Clin Transl Immunology (2017) 0.75
Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma. Nat Commun (2016) 0.75
Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis. J Cancer (2017) 0.75
LIGHTing tumor up for checkpoint blockade. Oncotarget (2016) 0.75
De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol (2017) 0.75
The role of dendritic cells in cancer. Semin Immunopathol (2016) 0.75
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma. Int J Mol Sci (2017) 0.75
Resistance to immunotherapy: clouds in a bright sky. Invest New Drugs (2017) 0.75
Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol (1997) 6.88
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Chemokines and cell migration in secondary lymphoid organs. Science (1999) 5.18
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 4.17
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Development and maturation of secondary lymphoid tissues. Annu Rev Immunol (1999) 3.69
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol (2005) 3.02
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014) 2.50
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol (2006) 2.33
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med (1997) 1.96
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer (2014) 1.92
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79
Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med (1989) 1.76
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015) 1.68
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60
Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol Res (1999) 1.57
Innate immune recognition of cancer. Annu Rev Immunol (2015) 1.52
Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity (2006) 1.40
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm (2010) 1.36
HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol (2009) 1.34
Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell (2014) 1.31
Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J Clin Invest (2003) 1.27
Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther (2012) 1.24
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol (2013) 1.20
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol (2015) 1.07
Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res (2006) 1.01
Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol Rev (2009) 0.98
Direct and indirect roles of the LTbetaR pathway in central tolerance induction. Trends Immunol (2010) 0.89
Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother (2015) 0.87
Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. Cancer Immunol Res (2015) 0.84
LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res (2012) 0.84
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol (2016) 0.75